Monjuvi (tafasitamab-cxix)

Adult Dosing .

Dosage forms:  INJ

Special Note

[drug name clarification]

Info: nonproprietary name = tafasitamab-cxix

[uses, dosing may vary]

Info: refer to institution protocols and pkg insert prior to prescribing for uses, premeds, and dosing incl. toxicity-related dose adjustments

diffuse large B-cell lymphoma, relapsed or refractory

[12 mg/kg/dose IV x1 on days 1, 4, 8, 15, 22 of 28-day cycle for cycle 1, then 12 mg/kg/dose IV x1 on days 1, 8, 15, 22 of 28-day cycle for cycles 2-3, then 12 mg/kg/dose IV x1 on days 1, 15 of 28-day cycle starting cycle 4 until dz progression]

Info: for pts ineligible for autologous HSCT; use w/ lenalidomide for up to first 12 cycles

follicular lymphoma, relapsed or refractory

[12 mg/kg/dose IV x1 on days 1, 8, 15, 22 of 28-day cycle for cycles 1-3, then 12 mg/kg/dose IV x1 on days 1, 15 of 28-day cycle for cycles 4-12]

Info: use w/ lenalidomide and rituximab

renal dosing

[see below]

CrCl >15: no adjustment; CrCl <15: not defined

HD/PD: not defined

hepatic dosing

[see below]

bilirubin 1-3x ULN or AST >ULN: no adjustment; bilirubin >3x ULN: not defined

Peds Dosing .

Peds dosing is currently unavailable or not applicable for this drug.